Abbott Laboratories' stock has dropped about 35% from its peak of $141.23 in March 2025 to $92.48 by April 2026, marking one of the steepest declines in its history, surpassing even the 2008-09 financial crisis drop. Despite this, Abbott's management projects adjusted diluted earnings per share between $5.38 and $5.58 for fiscal 2026, with expected net sales growth of 6.5% to 7.5%. The stock currently trades at a forward price-to-earnings ratio of 16.9 for 2026 and 15.2 for 2027, suggesting a potentially attractive valuation. The author has initiated a position in Abbott shares, indicating confidence in the company's future performance amid the recent sell-off.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
